Two Sigma Investments LP bought a new stake in Cellectis SA (NASDAQ:CLLS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,792 shares of the biotechnology company’s stock, valued at approximately $180,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Cellectis by 24,158.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after purchasing an additional 48,317 shares during the last quarter. Financial Gravity Companies Inc. purchased a new position in Cellectis during the 4th quarter worth $71,000. Point72 Asset Management L.P. grew its position in Cellectis by 118.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 156,133 shares of the biotechnology company’s stock worth $4,406,000 after purchasing an additional 84,533 shares during the last quarter. Macquarie Group Ltd. purchased a new position in Cellectis during the 3rd quarter worth $5,390,000. Finally, Morgan Stanley grew its position in Cellectis by 25.2% during the 3rd quarter. Morgan Stanley now owns 481,450 shares of the biotechnology company’s stock worth $13,586,000 after purchasing an additional 96,847 shares during the last quarter. Hedge funds and other institutional investors own 29.58% of the company’s stock.
Shares of NASDAQ CLLS traded down $0.73 during midday trading on Thursday, hitting $18.98. The company had a trading volume of 89,200 shares, compared to its average volume of 126,392. Cellectis SA has a twelve month low of $15.34 and a twelve month high of $31.57. The stock has a market capitalization of $820.04 million, a price-to-earnings ratio of -9.83 and a beta of 1.77.
Several brokerages have issued reports on CLLS. BidaskClub raised shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, April 1st. William Blair initiated coverage on shares of Cellectis in a report on Wednesday, March 13th. They issued an “outperform” rating on the stock. Barclays reaffirmed a “buy” rating and issued a $50.00 target price on shares of Cellectis in a report on Wednesday, March 13th. Finally, Citigroup lowered their target price on shares of Cellectis from $37.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, March 11th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $32.00.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Read More: How a Back-End Load Mutual Fund Works
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.